R. Vuppalanchi, R. Saxena, A. Storniolo
May 1, 2017
Citations
0
Influential Citations
29
Citations
Quality indicators
Journal
Hepatology
Abstract
Palbociclib is an oral, small-molecule, specific, and reversible inhibitor of cyclin-dependent kinases 4 and 6, recently approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative, metastatic breast cancer. Registration trials witnessed a few treatment-emergent liver safety issues, with one liver-related death that was not considered to be related to palbociclib. In this postmarketing report, we characterize two patients with hepatic failure and liver-related death following treatment with palbociclib.